SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001618835-22-000082
Filing Date
2022-04-07
Accepted
2022-04-06 19:36:10
Documents
14
Period of Report
2022-04-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K evfm-20220404.htm   iXBRL 8-K 43757
2 EX-10.1 evfm-ex101xadjuvantfirstam.htm EX-10.1 31515
  Complete submission text file 0001618835-22-000082.txt   267235

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20220404.xsd EX-101.SCH 2292
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evfm-20220404_def.xml EX-101.DEF 16429
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20220404_lab.xml EX-101.LAB 31730
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20220404_pre.xml EX-101.PRE 17165
8 EXTRACTED XBRL INSTANCE DOCUMENT evfm-20220404_htm.xml XML 14007
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 22811814
SIC: 2834 Pharmaceutical Preparations